Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: A functional and transcriptome profiling‐based study. Issue 6 (5th March 2019)

• Record Type: Journal Article
• Authors: He, Hongjuan; Chen, Erfei; Lei, Lei; Yan, Bianbian; Zhao, Xiaojuan; Zhu, Ziqing; Li, Qiqi; Zhang, Pan; Zhang, Wei; Xing, Jinliang; Du, Le; Dong, Jing; Yang, Jin
• Is Part Of: Molecular carcinogenesis. Volume 58:Issue 6(2019)
• Page Start: 957
• Page End: 966
• Publication Date: 2019-03-05
• Subjects: gene overexpression and depletion -- gene mutation -- SARDH -- signaling pathway -- sporadic colorectal cancer; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22984
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : Sporadic colorectal cancer (sCRC) is one of the leading causes of cancer death worldwide. As a highly heterogeneous complex disease, the currently reported classical genetic markers for sCRC, including APC, KRAS, BRAF, and TP53 gene mutations and epigenetic alterations, can explain only some sCRC patients. Here, we first reported a deleterious c.551C>T mutation in SARDH in sCRC. SARDH was identified as a novel tumor suppressor gene and was abnormally decreased in sCRC at both the transcriptional and the translational level. SARDH mRNA levels were also down‐regulated in oesophageal cancer, lung cancer, liver cancer, and pancreatic cancer in the TCGA database. SARDH overexpression inhibited the proliferation, migration, and invasion of CRC cell lines, whereas its depletion improved these processes. SARDH overexpression was down‐regulated in multiple pathways, especially in the chemokine pathway. The SARDH transcript level was positively correlated with the methylation states of CXCL1 and CCL20 . Therefore, we concluded that SARDH depletion is involved in the development of sCRC.